



Editorial Board Members' Collection Series: Utilization of Immune Checkpoint Inhibitors: Past, Present and Future Therapeutics in Cancer

Guest Editors:

Prof. Dr. David R. Wallace

Department of Pharmacology & Physiology, School of Biomedical Science, Oklahoma State University Center for Health Sciences, Tulsa, OK 74107-1898, USA

Prof. Giuseppe Murdaca

Department of Internal Medicine, University of Genoa, Genoa, Italy

Deadline for manuscript submissions:

closed (31 March 2023)

Message from the Guest Editors

The focus on immune checkpoint involvement in the development of cancer has increased dramatically over the last decade. Dysfunctions in these pathways, leading to excessive activation, inhibits the cells' normal response to damage, leading to unchecked cellular growth. Early pathways, such as the programmed cell death receptor (PD-1) or the cytotoxic lymphocyte-associated molecule-4 (CTLA-4) involved inhibition of the pathway to slow tumor growth. More recent, some checkpoint pathways require stimulation to exert anti-tumor actions. These pathways include CD40 and OX40 pathways. Modifying the tumor microenvironment, thus interfering with cellular energy production and utilization, has become another area of intense interest. The goal of the series is to provide a collection of review and original articles that describe the work that has been done and the outlook for therapeutic developments that target immune checkpoints to attenuate or block cancer development.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI